Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,467,650 papers from all fields of science
Search
Sign In
Create Free Account
DORA-22
Known as:
((2R,5R)-5-((5-fluoropyridin-2-yl)oxymethyl)-2-methylpiperidin-1-yl)-(5-fluoro-2-pyrimidin-2-ylphenyl)methanone
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (3)
Orexin Receptor Antagonists
Piperidines
Triazoles
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model.
Mackenzie C. Gamble
,
Fumi Katsuki
,
J. G. McCoy
,
R. Strecker
,
J. McKenna
Sleep
2019
Corpus ID: 203982998
Insomnia-related sleep disruption can contribute to impaired learning and memory. Treatment of insomnia should ideally improve…
Expand
2017
2017
Excitation of GABAergic Neurons in the Bed Nucleus of the Stria Terminalis Triggers Immediate Transition from Non-Rapid Eye Movement Sleep to Wakefulness in Mice
Shota Kodani
,
Shingo Soya
,
T. Sakurai
Journal of Neuroscience
2017
Corpus ID: 10757251
Emotionally salient situations usually trigger arousal along with autonomic and neuroendocrine reactions. To determine whether…
Expand
2017
2017
The dual orexin receptor antagonist, DORA‐22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine
Lihang Yao
,
Andres D. Ramirez
,
+8 authors
A. Gotter
Journal of Neurochemistry
2017
Corpus ID: 25573186
Chronic insomnia is defined as a persistent difficulty with sleep initiation maintenance or non‐restorative sleep. The…
Expand
2016
2016
Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.
P. Tannenbaum
,
S. Tye
,
+9 authors
J. Renger
Sleep
2016
Corpus ID: 33944581
STUDY OBJECTIVES In addition to enhancing sleep onset and maintenance, a desirable insomnia therapeutic agent would preserve…
Expand
2016
2016
Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain
T. Mcdonald
,
Hongyu A Liang
,
+6 authors
J. Renger
Journal of neurogenetics
2016
Corpus ID: 34341086
Abstract Orexin signaling, known to modulate arousal and vigilance, is also involved in nociception as orexin neurons project to…
Expand
2014
2014
Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs
P. Tannenbaum
,
Joanne Stevens
,
+11 authors
J. Renger
Frontiers in Behavioral Neuroscience
2014
Corpus ID: 5928541
The ability to awaken from sleep in response to important stimuli is a critical feature of normal sleep, as is maintaining sleep…
Expand
2014
2014
Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators
A. Gotter
,
S. Garson
,
+11 authors
J. Renger
BMC Neuroscience
2014
Corpus ID: 13734143
BackgroundThe current standard of care for insomnia includes gamma-aminobutyric acid receptor A (GABAA) activators, which promote…
Expand
Highly Cited
2013
Highly Cited
2013
Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition
J. Uslaner
,
S. Tye
,
+18 authors
J. Renger
Science Translational Medicine
2013
Corpus ID: 206681369
Selective orexin receptor antagonism promotes sleep at doses lower than those that impair attention and memory in contrast to the…
Expand
2013
2013
Quantitative Electroencephalography Within Sleep/Wake States Differentiates GABAA Modulators Eszopiclone and Zolpidem From Dual Orexin Receptor Antagonists in Rats
Steven V. Fox
,
A. Gotter
,
+14 authors
J. Renger
Neuropsychopharmacology
2013
Corpus ID: 21228716
Dual orexin receptor antagonists (DORAs) induce sleep by blocking orexin 1 and orexin 2 receptor-mediated activities responsible…
Expand
Highly Cited
2012
Highly Cited
2012
Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia
C. Winrow
,
A. Gotter
,
+12 authors
J. Renger
Neuropharmacology
2012
Corpus ID: 35304627
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE